ArticleWorld journal of surgical oncology2026
Analysis of the efficacy of camrelizumab/cetuximab neoadjuvant therapy in patients with loco-regionally advanced laryngeal and hypopharyngeal cancer and the prognostic value of NLR/SII.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Ferrous-Supply-Regenerating Lipid Nanoparticle Integrating RNAi Induces Ferroptosis for Cancer Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLaryngeal and hypopharyngeal squamous cell carcinomas are among the most common head and neck malignancies, presenting a dual clinical challenge of achieving tumor eradication while preserving laryngeal function. This study evaluated the efficacy and preservation of laryngeal function effects of different neoadjuvant treatment regimens in patients.
methodsThis retrospective study analyzed data from 110 patients with loco-regionally advanced laryngeal and hypopharyngeal cancer. Patients were categorized into three groups based on the neoadjuvant treatment regimens administered: TP chemotherapy group (albumin-bound paclitaxel plus cisplatin), camrelizumab plus TP chemotherapy group, and cetuximab plus TP chemotherapy group. To make a Kaplan-Meier survival curve plot for 3 groups and do a log-rank test on these groups. We executed receiver operation capability (ROC) curve examination and a multivariate Coxproportional dangers regression to recognize separate prognostic determinants for 2-year overall survival (OS).
resultsCompared with TP chemotherapy alone, camrelizumab plus TP chemotherapy demonstrated significant improvements in multiple endpoints (all P < 0.05). The objective response rate (ORR) in the camrelizumab plus TP chemotherapy group was 90.0%, the 2-year progression-free survival (PFS) rate was 75.0%, and the 2-year laryngectomy-free survival (LFS) rate was 67.5%. However, the 2-year OS rate was 80.0%, indicating no significant improvement (P > 0.05). The cetuximab plus TP chemotherapy group did not demonstrate significant improvements in any of the above three endpoints (all P > 0.05). No significant difference was observed in the incidence of major adverse events among the three groups (P > 0.05). Cox regression analysis revealed that the systemic immunoinflammatory index (SII), neutrophil-lymphocyte ratio (NLR), and N stage were independent prognostic factors. ROC curve analysis demonstrated that the areas under the curve (AUC) for SII and NLR in predicting prognosis were 0.839 (95% confidence interval [CI]: 0.755-0.923) and 0.853 (95% CI: 0.772-0.934), respectively.
conclusionIn patients with loco-regionally advanced laryngeal and hypopharyngeal carcinoma, combining camrelizumab with TP chemotherapy demonstrates favorable short-term efficacy and laryngeal preservation rates while maintaining an acceptable safety profile. The inflammatory immune markers SII and NLR have valuable predictive utility in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.